ESR1 and breast cancer: This heterogeneity explains why there is not an incisive therapy for BC treatment and highlights how it is important to develop new therapeutic strategies, alternative to the currently used drugs, such as Tamoxifen or Trastuzumab or Lapatinib, which are only useful when the target proteins (ER or Her2) are expressed.